Immunogenicity of radiotherapy on bone metastases from prostate adenocarcinoma: What is the future for the combination with radiotherapy/immunotherapy?
Tumori Journal · 2024
DOI: 10.1177/03008916241249366 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Tumori Journal, 2024. Verfasst von Pierre Cornillon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, France. Hauptthemen laut MEDLINE: Bone Neoplasms, Immunotherapy, Prostatic Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 82 Literaturangaben.
Abstract (Originalsprache)
Bone metastatic prostate cancers (PCa) are resistant to usual immunotherapies such as checkpoint inhibitors. The main hypothesis related to this immunoresistance is the lack of antigens to stimulate anti-tumor immunity. External radiation is a potential inducer antigens presentation and thus to immunotherapy proprieties. The aim of this review is to describe the tumor microenvironment specificities, especially in bone metastasis and the immune modifications after radiation therapy on a metastatic castration-resistant PCa population. PCa microenvironment is immunosuppressive because of many tumor factors. The complex interplay between PCa cells and bone microenvironment leads to a ‘vicious circle’ promoting bone metastasis. Furthermore, the immune and bone systems, are connected through an osteoclastogenic cytokine: the Receptor Activator Nuclear Factor Kappa B ligand. Adapted doses of ionizing radiation play a dual role on the tumor. Indeed, radiotherapy leads to immunogenicity by inducing damage associated with molecular patterns. However, it also induces an immunosuppressive effect by increasing the number of immunosuppressive cells. Interestingly, the abscopal effect could be used to optimize immunotherapy potential, especially on bone metastasis. Radiotherapy and immunotherapy combination is a promising strategy, however further studies are necessary to determine the more efficient types of radiation and to control the abscopal effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, France.
- Department of Radiotherapy, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, France.
- Department of Medical Oncology, IMMUCARE, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices de Lyon, Pierre-Bénite, France.
- Department of Medical Oncology, Medipole Lyon Villeurbanne Mutualist Clinic, Lyon, France.
ORCID-Profile: Wafa Bouleftour, Thomas Reynaud
Zitieren
APA
Cornillon, P., Bouleftour, W., Reynaud, T., Pigne, G., Maillet, D., Hamizi, S., & Beguinot, M. (2024). Immunogenicity of radiotherapy on bone metastases from prostate adenocarcinoma: What is the future for the combination with radiotherapy/immunotherapy?. Tumori Journal. https://doi.org/10.1177/03008916241249366
Vancouver
Cornillon P, Bouleftour W, Reynaud T, Pigne G, Maillet D, Hamizi S, et al. Immunogenicity of radiotherapy on bone metastases from prostate adenocarcinoma: What is the future for the combination with radiotherapy/immunotherapy?. Tumori Journal. 2024. doi:10.1177/03008916241249366
BibTeX
@article{Cornillon2024,
author = {Cornillon, Pierre and Bouleftour, Wafa and Reynaud, Thomas and Pigne, Gregoire and Maillet, Denis and Hamizi, Salima and Beguinot, Marie},
title = {Immunogenicity of radiotherapy on bone metastases from prostate adenocarcinoma: What is the future for the combination with radiotherapy/immunotherapy?},
journal = {Tumori Journal},
year = {2024},
doi = {10.1177/03008916241249366}
}
EUVIMED